Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer

International Journal of Oncology

Volumn 34, Issue 5, 2009, Pages 1209-1220

  Kunigal, Sateesh ^a   Lakka, Sajani S ^a   Sodadasu, Prasanna Kumar ^a   Estes, Norman ^a   Rao, Jasti S ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Apoptosis; Fas Fas L; Stat3

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; FAS ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BCL XL; SMALL INTERFERING RNA; STAT3 PROTEIN; SURVIVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; BREAST NEOPLASMS; CELL SURVIVAL; FAS LIGAND PROTEIN; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; MODELS, BIOLOGICAL; PROTEIN BINDING; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67649445779     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000249     Document Type: Article

References (49)

1. Clevenger CV: Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 165: 1449-1460, 2004.
2. Takeda K and Akira S: STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev 11: 199-207, 2000.
3. Yu H and Jove R: The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 4: 97-105, 2004.
4. Shushakova N, Tkachuk N, Dangers M, Tkachuk S, Park JK, Hashimoto K, Haller H and Dumler I: Urokinase-induced activation of the gp130/Tyk2/ Stat3 pathway mediates a pro-inflammatory effect in human mesangial cells via expression of the anaphylatoxin C5a receptor. J Cell Sci 118: 2743-2753, 2005.
5. Zhong Z, Wen Z and Darnell JE Jr: Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 95-98, 1994.
6. Bromberg J: Stat proteins and oncogenesis. J Clin Invest 109: 1139-1142, 2002.
7. Darnell JE Jr: STATs and gene regulation. Science 277: 1630-1635, 1997.
8. Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I and Bromberg JF: Requirement of matrix metallo-proteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA 101: 10602-10607, 2004.
9. Garcia R, Yu CL, Hudnall A, Catlett R, Nelson KL, Smithgall T, Fujita DJ, Ethier SP and Jove R: Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 8: 1267-1276, 1997.
10. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R and Sebti SM: Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63: 1270-1279, 2003.
11. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF and Grandis JR: Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 100: 4138-4143, 2003.
12. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A and Roifman CM: Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379: 645-648, 1996.
13. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J and Jove R: Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62: 6659-6666, 2002.
14. Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N, Kitaoka T, Fukada T, Hibi M and Hirano T: A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 15: 3651-3658, 1996.
15. Ni Z, Lou W, Leman ES and Gao AC: Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res 60: 1225-1228, 2000.
16. Konnikova L, Kotecki M, Kruger MM and Cochran BH: Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 3: 23-31, 2003.
17. Lee SO, Lou W, Qureshi KM, Mehraein-Ghomi F, Trump DL and Gao AC: RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 60: 303-309, 2004.
18. Buettner R, Mora LB and Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945-954, 2002.
19. Aoki Y, Feldman GM and Tosato G: Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101: 1535-1542, 2003.
20. Reed JC: Bcl-2 family proteins. Oncogene 17: 3225-3236, 1998.
21. Bromberg J and Darnell JE Jr: The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19: 2468-2473, 2000.
22. Catlett-Falcone R, Dalton WS and Jove R: STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. Curr Opin Oncol 11: 490-496, 1999.
23. Zamore PD, Tuschl T, Sharp PA and Bartel DP: RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101: 25-33, 2000.
24. Li N, Ragheb K, Lawler G, Sturgis J, Rajwa B, Melendez JA and Robinson JP: Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem 278: 8516-8525, 2003.
25. Desrivieres S, Kunz C, Barash I, Vafaizadeh V, Borghouts C and Groner B: The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition. J Mammary Gland Biol Neoplasia 11: 75-87, 2006.
26. Groner B and Hennighausen L: Linear and cooperative signaling: roles for Stat proteins in the regulation of cell survival and apoptosis in the mammary epithelium. Breast Cancer Res 2: 149-153, 2000.
27. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997.
28. Song RX and Santen RJ: Apoptotic action of estrogen. Apoptosis 8: 55-60, 2003.
29. Chinnaiyan AM, O'Rourke K, Tewari M and Dixit VM: FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505-512, 1995.
30. Schaub FJ, Liles WC, Ferri N, Sayson K, Seifert RA and Bowen-Pope DF: Fas and Fas-associated death domain protein regulate monocyte chemoattractant protein-1 expression by human smooth muscle cells through caspase- and calpain-dependent release of interleukin-1alpha. Circ Res 93: 515-522, 2003.
31. Lademann U, Cain K, Gyrd-Hansen M, Brown D, Peters D and Jaattela M: Diarylurea compounds inhibit caspase activation by preventing the formation of the active 700-kilodalton apoptosome complex. Mol Cell Biol 23: 7829-7837, 2003.
32. Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, Eweis I, Wloch M, Livingston S, Seijo E, Cantor A, Lee JH, Beam CA, Sullivan D, Jove R and Muro-Cacho CA: Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 12: 20-28, 2006.
33. Berishaj M, Gao SP, Ahmed S, Leslie K, Al-Ahmadie H, Gerald WL, Bornmann W and Bromberg JF: Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 9: R32, 2007.
34. Semizarov D, Frost L, Sarthy A, Kroeger P, Halbert DN and Fesik SW: Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci USA 100: 6347-6352, 2003.
35. Toillon RA, Descamps S, Adriaenssens E, Ricort JM, Bernard D, Boilly B and Le BX: Normal breast epithelial cells induce apoptosis of breast cancer cells via Fas signaling. Exp Cell Res 275: 31-43, 2002.
36. Xia C, Zhao H and Tang X: [The expressions of Fas and Fas-L in human breast invasive ductal carcinomas and their surrounding tissues]. Zhonghua Wai Ke Za Zhi 37: 648-650, 1999.
37. Friesen C, Fulda S and Debatin KM: Cytotoxic drugs and the CD95 pathway. Leukemia 13: 1854-1858, 1999.
38. Mo YY and Beck WT: DNA damage signals induction of fas ligand in tumor cells. Mol Pharmacol 55: 216-222, 1999.
39. Micheau O, Solary E, Hammann A, Martin F and Manche-Boitrel MT: Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst 89: 783-789, 1997.
40. Boldin MP, Goncharov TM, Goltsev YV and Wallach D: Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85: 803-815, 1996.
41. Cho SG and Choi EJ: Apoptotic signaling pathways: caspases and stress-activated protein kinases. J Biochem Mol Biol 35: 24-27, 2002.
42. Hsu H, Shu HB, Pan MG and Goeddel DV: TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84: 299-308, 1996.
43. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D and Reed JC: Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 95: 4997-5002, 1998.
44. Marzo I, Brenner C, Zamzami N, Jurgensmeier JM, Susin SA, Vieira HL, Prevost MC, Xie Z, Matsuyama S, Reed JC and Kroemer G: Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 281: 2027-2031, 1998.
45. Narita M, Shimizu S, Ito T, Chittenden T, Lutz RJ, Matsuda H and Tsujimoto Y: Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci USA 95: 14681-14686, 1998.
46. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, et al: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43, 1995.
47. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS and Dixit VM: Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81: 801-809, 1995.
48. Scott SL, Higdon R, Beckett L, Shi XB, Vere White RW, Earle JD and Gumerlock PH: BCL2 antisense reduces prostate cancer cell survival following irradiation. Cancer Biother Radiopharm 17: 647-656, 2002.
49. Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao D, Kalvakolanu DV, Kopecko DJ, Zhao X and Xu DQ: Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res 11: 6333-6341, 2005.